Digoxin-amiodarone Combination is Associated With Excess All-cause Mortality in Patients With Atrial Fibrillation.

Scientific Reports
Jiun-Yang ChiangJiunn-Lee Lin

Abstract

Combination use of digoxin and other medications might lead to worse outcomes in patients with atrial fibrillation (AF). We sought to investigate whether digoxin-amiodarone combination would lead to worse outcome than digoxin alone in patients with AF. Adult patients with AF and received digoxin treatment from random samples of 1,000,000 individuals covered by the National Health Insurance in Taiwan were included. Baseline characteristics including risk factors and medications were matched by propensity score (PS) in those with and without addition of amiodarone treatment. A total of 5,040 AF patients taking digoxin therapy was included. PS matching identified 1,473 patients receiving digoxin-amiodarone combination and 2,660 patients receiving digoxin with a median follow-up of 1,331 days. Digoxin-amiodarone combination was associated with increased all-cause mortality (adjusted hazard ratio (HR): 1.640, 95% confidence interval (CI): 1.470-1.829, P < 0.001). The risk of mortality increased regardless of duration of combination. Risk of sudden cardiac death was not increased in the combination group (HR: 1.304, 95% CI: 1.049-1.622, P = 0.017). Death due to non-arrhythmic cardiac disease, cerebrovascular disease, and other vascul...Continue Reading

References

Apr 1, 1987·Journal of Cardiovascular Pharmacology·G SantostasiS Dalla-Volta
Jan 1, 1985·Journal of the American College of Cardiology·P E FensterC D Hanson
Mar 1, 1984·The Journal of Pediatrics·G KorenS M MacLeod
Apr 1, 1993·Clinical Pharmacology and Therapeutics·A MordelD Ezra
Feb 6, 1997·Health Policy·T L Chiang
Feb 18, 2003·JAMA : the Journal of the American Medical Association·Saif S RathoreHarlan M Krumholz
May 22, 2003·Health Affairs·Jui-Fen Rachel Lu, William C Hsiao
Apr 21, 2005·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Julio A ChirinosYeon S Ahn
Jun 1, 2006·Circulation·Mihai GheorghiadeWilson S Colucci
Aug 9, 2007·European Journal of Clinical Pharmacology·Pär HallbergUNKNOWN RIKS-HIA group
Apr 27, 2011·American Journal of Therapeutics·Ajay VallakatiJacob Shani
Nov 16, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN PALLAS Investigators
Aug 28, 2012·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·A John CammUNKNOWN Document Reviewers
Apr 9, 2013·Journal of the American College of Cardiology·Jeffrey D WesslerRobert P Giugliano
May 6, 2015·European Heart Journal·Mate VamosStefan H Hohnloser

❮ Previous
Next ❯

Software Mentioned

ROCKET AF
SPSS

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.